FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012199194> ?p ?o ?g. }

• W2012199194 abstract "At present we report the results of a prospective, non-randomized open trial, conducted on follicular lymphoma (FL) patients by the Gruppo Italiano per lo Studio dei Linfomi (GISL), after a median follow-up of 62.6 months. Seventy-three patients with FL were registered to the study and treated with combination chemotherapy consisting of cyclophosphamide, epidoxorubicin, vincristine, bleomycin and prednisone, weekly administered every 4 weeks. After chemotherapy, involved-field radiotherapy was delivered in case of either localized, bulky and extranodal disease at presentation or limited residual disease at the end of chemotherapy. Patient received four or eight chemotherapy courses in case of localized or advanced disease, respectively. The overall response rate at the end of the treatment program was 97.3%, with 78.1% CR and 19.2% PR. CR rate was 94.3 and 63.1% in stage I-II and III-IV, respectively (p = 0.006). Beside the stage, response rate was significantly influenced by bone marrow involvement, and the number of extranodal sites. Relapse free survival was 60.8% at 5 years in the whole series; in localized disease it was 70.3 vs. 44.8% in advanced disease (p = 0.044). Relapse free survival was significantly influenced by stage, bone marrow involvement, number of extranodal sites and International Prognostic Index (IPI) score. The overall 5-year survival rate was 90.2%; being 95.6% for patients with stage I-II and 85.1% for those III-IV (p = 0.0133). In addition, both IPI and Italian Lymphoma Intergroup (ILI) score had a significant impact on survival. The toxicity profile of the treatment was acceptable. From the results of this prospective study it is possible to conclude that this regimen and the whole treatment program is effective as first line therapy for the general population of FL. In particular the BACOP schedule is a valid anthracycline-containing regimen, and in this respect suitable to be considered as a treatment option." @default.
• W2012199194 created "2016-06-24" @default.
• W2012199194 creator A5013445468 @default.
• W2012199194 creator A5016803459 @default.
• W2012199194 creator A5022153283 @default.
• W2012199194 creator A5031216906 @default.
• W2012199194 creator A5035398527 @default.
• W2012199194 creator A5038901412 @default.
• W2012199194 creator A5042520870 @default.
• W2012199194 creator A5044602168 @default.
• W2012199194 creator A5046680192 @default.
• W2012199194 creator A5049017377 @default.
• W2012199194 creator A5049158191 @default.
• W2012199194 creator A5057259286 @default.
• W2012199194 creator A5061896020 @default.
• W2012199194 creator A5066201212 @default.
• W2012199194 creator A5074749942 @default.
• W2012199194 date "2002-01-01" @default.
• W2012199194 modified "2023-10-11" @default.
• W2012199194 title "Bleomycin, Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)" @default.
• W2012199194 cites W125057240 @default.
• W2012199194 cites W1504115866 @default.
• W2012199194 cites W1921096083 @default.
• W2012199194 cites W1921508210 @default.
• W2012199194 cites W1981928449 @default.
• W2012199194 cites W1990892742 @default.
• W2012199194 cites W2008402216 @default.
• W2012199194 cites W2010375918 @default.
• W2012199194 cites W2042483573 @default.
• W2012199194 cites W2082948115 @default.
• W2012199194 cites W2097411619 @default.
• W2012199194 cites W2097892163 @default.
• W2012199194 cites W2168926834 @default.
• W2012199194 cites W2222059886 @default.
• W2012199194 cites W2327208070 @default.
• W2012199194 cites W3024436806 @default.
• W2012199194 cites W4205736005 @default.
• W2012199194 cites W4231822924 @default.
• W2012199194 cites W4240713552 @default.
• W2012199194 cites W4249745132 @default.
• W2012199194 cites W4252168887 @default.
• W2012199194 doi "https://doi.org/10.1080/1042819021000006457" @default.
• W2012199194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12685834" @default.
• W2012199194 hasPublicationYear "2002" @default.
• W2012199194 type Work @default.
• W2012199194 sameAs 2012199194 @default.
• W2012199194 citedByCount "9" @default.
• W2012199194 countsByYear W20121991942016 @default.
• W2012199194 crossrefType "journal-article" @default.
• W2012199194 hasAuthorship W2012199194A5013445468 @default.
• W2012199194 hasAuthorship W2012199194A5016803459 @default.
• W2012199194 hasAuthorship W2012199194A5022153283 @default.
• W2012199194 hasAuthorship W2012199194A5031216906 @default.
• W2012199194 hasAuthorship W2012199194A5035398527 @default.
• W2012199194 hasAuthorship W2012199194A5038901412 @default.
• W2012199194 hasAuthorship W2012199194A5042520870 @default.
• W2012199194 hasAuthorship W2012199194A5044602168 @default.
• W2012199194 hasAuthorship W2012199194A5046680192 @default.
• W2012199194 hasAuthorship W2012199194A5049017377 @default.
• W2012199194 hasAuthorship W2012199194A5049158191 @default.
• W2012199194 hasAuthorship W2012199194A5057259286 @default.
• W2012199194 hasAuthorship W2012199194A5061896020 @default.
• W2012199194 hasAuthorship W2012199194A5066201212 @default.
• W2012199194 hasAuthorship W2012199194A5074749942 @default.
• W2012199194 hasConcept C126322002 @default.
• W2012199194 hasConcept C141071460 @default.
• W2012199194 hasConcept C2776232574 @default.
• W2012199194 hasConcept C2776694085 @default.
• W2012199194 hasConcept C2776755627 @default.
• W2012199194 hasConcept C2777058707 @default.
• W2012199194 hasConcept C2778720950 @default.
• W2012199194 hasConcept C2779338263 @default.
• W2012199194 hasConcept C2779429289 @default.
• W2012199194 hasConcept C71924100 @default.
• W2012199194 hasConcept C90924648 @default.
• W2012199194 hasConceptScore W2012199194C126322002 @default.
• W2012199194 hasConceptScore W2012199194C141071460 @default.
• W2012199194 hasConceptScore W2012199194C2776232574 @default.
• W2012199194 hasConceptScore W2012199194C2776694085 @default.
• W2012199194 hasConceptScore W2012199194C2776755627 @default.
• W2012199194 hasConceptScore W2012199194C2777058707 @default.
• W2012199194 hasConceptScore W2012199194C2778720950 @default.
• W2012199194 hasConceptScore W2012199194C2779338263 @default.
• W2012199194 hasConceptScore W2012199194C2779429289 @default.
• W2012199194 hasConceptScore W2012199194C71924100 @default.
• W2012199194 hasConceptScore W2012199194C90924648 @default.
• W2012199194 hasLocation W20121991941 @default.
• W2012199194 hasLocation W20121991942 @default.
• W2012199194 hasOpenAccess W2012199194 @default.
• W2012199194 hasPrimaryLocation W20121991941 @default.
• W2012199194 hasRelatedWork W1544519462 @default.
• W2012199194 hasRelatedWork W1828636203 @default.
• W2012199194 hasRelatedWork W1862207694 @default.
• W2012199194 hasRelatedWork W1930245694 @default.
• W2012199194 hasRelatedWork W1999949061 @default.
• W2012199194 hasRelatedWork W2002979492 @default.
• W2012199194 hasRelatedWork W2037252592 @default.
• W2012199194 hasRelatedWork W2038085407 @default.
• W2012199194 hasRelatedWork W2089712138 @default.
• W2012199194 hasRelatedWork W2095793998 @default.

• next